Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial

HFCAS OpenIR

	Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial
	Li, Ning 1; Zhu, Jianqing 2; Yin, Rutie 3; Wang, Jing 4; Pan, Lingya 5; Kong, Beihua 6; Zheng, Hong 7; Liu, Jihong 8; Wu, Xiaohua 9; Wang, Li 10; Huang, Yi 11; Wang, Ke12 ; Zou, Dongling 13; Zhao, Hongqin 14; Wang, Chunyan 15; Lu, Weiguo 16; Lin, An 17; Lou, Ge 18; Li, Guiling 19; Qu, Pengpeng 20; Yang, Hongying 21; Zhen, Xiaoa 22; Hang, Wenzhao 23; Hou, Jianmei 23; Banerjee, Ashish 24; Wu, Lingying 1
	2022-11-01
发表期刊	ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
ISSN	1743-7555
收录类别	SCI
语种	英语
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000871956500189
出版者	WILEY
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/130036
专题	中国科学院合肥物质科学研究院
作者单位	1.Chinese Acad Med Sci & Peking UnionMed Coll, Nat Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 3.Sichuan Univ, West China Univ Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Peoples R China 4.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China 5.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China 6.Shandong Univ, Qilu Hosp, Jinan, Peoples R China 7.Peking Univ Canc Hosp & Inst, Beijing, Peoples R China 8.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China 9.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 10.Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China 11.Huazhong Univ Sci & Technol, Hubei Canc Hosp, Affiliated Canc Hosp, Tongji Med Coll, Wuhan, Peoples R China 12.Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China 13.Chongqing Univ, Chongqing Canc Hosp, Canc Hosp, Chongqing, Peoples R China 14.Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China 15.China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Shenyang, Peoples R China 16.Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou, Peoples R China 17.Fujian Med Univ, Fujian Canc Hosp, Canc Hosp, Fuzhou, Peoples R China 18.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China 19.Huazhong Univ Sci & Technol, Tongji Med Coll, Canc Ctr, Union Hosp, Wuhan, Peoples R China 20.Tianjin Cent Hosp Gynecol Obstet, Tianjin, Peoples R China 21.Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Kunming, Peoples R China 22.Zai Lab US LLC, Boston, MA USA 23.Zai Lab Shanghai Co Ltd, Shanghai, Peoples R China 24.GSK, Melbourne, Australia
推荐引用方式 GB/T 7714	Li, Ning,Zhu, Jianqing,Yin, Rutie,et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,2022,18.
APA	Li, Ning.,Zhu, Jianqing.,Yin, Rutie.,Wang, Jing.,Pan, Lingya.,...&Wu, Lingying.(2022).Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial.ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,18.
MLA	Li, Ning,et al."Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial".ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 18(2022).